• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    CooperCompanies Acquires obp Surgical, Expanding CooperSurgical's Portfolio of Leading Medical Devices

    8/1/24 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care
    Get the next $COO alert in real time by email

    SAN RAMON, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) --  CooperCompanies (NASDAQ:COO), today announced that CooperSurgical has acquired obp Surgical, a U.S.-based medical device company with a suite of single-use cordless surgical retractors with an integrated multi-LED light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source, for approximately $100 million. The products being acquired generated approximately $14.5 million of trailing twelve-month revenue. The acquisition is expected to be neutral to Cooper's non-GAAP earnings per share in fiscal 2024 and accretive thereafter.

    "This acquisition is a great strategic fit that builds upon CooperSurgical's strong portfolio of leading medical devices," said Al White, President and Chief Executive Officer of CooperCompanies. "obp Surgical's differentiated products will integrate seamlessly into our business and allow us to provide clinicians with a broader range of innovative surgical technologies."

    The acquisition of obp Surgical's distinctive ONETRAC™ portfolio of surgical retractors and suction devices complements CooperSurgical's existing surgical portfolio including INSORB®, Lone Star®, and the Doppler Blood Flow Monitor.

    "Our acquisition of obp Surgical demonstrates our commitment to our customers, rooted in a dedication to upholding the highest standards," said Holly Sheffield, CooperSurgical President. "We are excited for our growing surgical portfolio to reach new heights with the addition of ONETRAC™ to the CooperSurgical product family, all to help ensure that healthcare providers are well-equipped with differentiated medical devices."

    CooperCompanies will report these assets as part of its Office and Surgical category within the CooperSurgical business beginning in its fiscal fourth quarter 2024.

    About CooperCompanies

    CooperCompanies (NASDAQ:COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies ("Cooper") has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

    About CooperSurgical

    CooperSurgical is a leading fertility and women's healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most in life. CooperSurgical is at the forefront of delivering innovative assisted reproductive technology (ART) and genomic solutions that enhance the work of ART professionals to the benefit of families. We currently offer over 600 clinically relevant medical devices to women's healthcare providers, including testing and treatment options.

    CooperSurgical is a wholly-owned subsidiary of CooperCompanies (Nasdaq: COO). CooperSurgical, headquartered in Trumbull, CT, produces and markets a wide array of products and services for use by women's health care clinicians. More information can be found at www.coopersurgical.com.

    About obp Surgical

    obp Surgical Corporation is committed to delivering single-use, self-contained, cordless illuminating surgical devices to improve and transform healthcare. Our innovative products are used in surgery centers and hospital operating rooms throughout the United States and worldwide. For more information on obp Surgical Corporation and the ONETRAC™ product lines, please visit www.obpsurgical.com.

    Forward-Looking Statements

    This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to plans, prospects, goals, strategies, future actions, events or performance and other statement of which are other than statements of historical fact, including statements regarding the benefits of the acquisition of obp Surgical assets, synergies and strategic plans related to the acquired business, and other financial expectations related to the acquisition. To identify these statements, look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases.  Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are: difficulties in integrating operations, adverse changes in the global or regional general business, political and economic conditions including the impact of continuing uncertainty and instability of certain countries, man-made or natural disasters, that could adversely affect our global markets, and the potential adverse economic impact and related uncertainty caused by these items; uncertainties in contractual relationships and pending transactions; changes in legal and regulatory requirements; and other factors described in the Securities and Exchange Commission filings for CooperCompanies (NASDAQ:COO), including the Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such disclosures may be updated in annual and quarterly filings. We caution investors that forward-looking statements reflect our analysis only on their stated date. We disclaim any intent to update them except as required by law.

    Contacts:

    CooperCompanies Investor Relations

    Kim Duncan

    Vice President, Investor Relations and Risk Management

    925-460-3663

    [email protected]



    CooperSurgical Media Relations

    [email protected]



    Primary Logo

    Get the next $COO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $COO

    DatePrice TargetRatingAnalyst
    7/22/2025$92.00Neutral → Outperform
    BNP Paribas Exane
    6/17/2025$94.00Hold → Buy
    Needham
    5/30/2025$76.00Overweight → Neutral
    Analyst
    8/29/2024$115.00 → $120.00Overweight
    Piper Sandler
    7/16/2024$107.00 → $115.00Hold → Buy
    Jefferies
    3/19/2024$125.00Neutral → Buy
    Redburn Atlantic
    3/13/2024$100.00 → $120.00Neutral → Overweight
    JP Morgan
    2/6/2024Sector Weight
    KeyBanc Capital Markets
    More analyst ratings

    $COO
    SEC Filings

    View All

    SEC Form SD filed by The Cooper Companies Inc.

    SD - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:20:18 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 10-Q filed by The Cooper Companies Inc.

    10-Q - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/30/25 4:19:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 8-K filed by The Cooper Companies Inc.

    8-K - COOPER COMPANIES, INC. (0000711404) (Filer)

    5/29/25 4:31:50 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cooper upgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane upgraded Cooper from Neutral to Outperform and set a new price target of $92.00

    7/22/25 7:47:24 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper upgraded by Needham with a new price target

    Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00

    6/17/25 7:46:56 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    Cooper downgraded by Analyst with a new price target

    Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00

    5/30/25 8:39:00 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $COO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CooperVision Canada Marks Fifth Year of Raising Awareness About Childhood Myopia and Treatment Options

    TORONTO, Aug. 18, 2025 /CNW/ - For the fifth year in a row, CooperVision Canada is investing in educating parents and raising awareness about myopia (aka nearsightedness) in children, emphasizing that it is more than just a blurry vision issue, it is a progressive condition that requires proactive management to help protect long-term eye health and preserve future opportunities for children. MiSight® 1 day contact lenses from CooperVision can help age-appropriate children with myopia reach their full potential. MiSight® 1 day is the first and only FDA approved* soft contact le

    8/18/25 4:16:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies to Participate in the Wells Fargo Healthcare Conference

    SAN RAMON, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today it will participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025. Al White, President and CEO, will represent the Company in a session scheduled at 3:00 PM ET. The webcast will be available to investors and other interested parties by accessing the CooperCompanies' website at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful moments through its two business units, CooperVision and CooperSurgical.

    8/14/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Director Carbone Barbara

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:16:23 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form 3 filed by new insider Carbone Barbara

    3 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    5/5/25 4:14:05 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Director Kozy William A converted options into 2,857 shares, increasing direct ownership by 10% to 31,149 units (SEC Form 4)

    4 - COOPER COMPANIES, INC. (0000711404) (Issuer)

    4/3/25 4:09:38 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Leadership Updates

    Live Leadership Updates

    View All

    CooperCompanies Appoints Barbara Carbone to Board of Directors

    SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in

    4/30/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    Evolus Announces Appointment of Albert G. White III to Board of Directors

    Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes

    7/1/24 8:00:00 AM ET
    $COO
    $EOLS
    Ophthalmic Goods
    Health Care
    Biotechnology: Pharmaceutical Preparations

    CooperCompanies Appoints Lawrence E. Kurzius to Board of Directors

    SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo

    11/30/23 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/16/24 4:57:01 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G filed by The Cooper Companies Inc.

    SC 13G - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/14/24 10:04:33 AM ET
    $COO
    Ophthalmic Goods
    Health Care

    SEC Form SC 13G/A filed by The Cooper Companies Inc. (Amendment)

    SC 13G/A - COOPER COMPANIES, INC. (0000711404) (Subject)

    2/13/24 5:02:29 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    $COO
    Financials

    Live finance-specific insights

    View All

    CooperCompanies Announces Release Date for Third Quarter 2025

    SAN RAMON, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report third quarter 2025 financial results on Wednesday, August 27, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 3665386. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beaut

    7/24/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Second Quarter 2025 Results

    SAN RAMON, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, today announced financial results for its fiscal second quarter ended April 30, 2025. Revenue increased 6% year-over-year to $1,002.3 million. CooperVision (CVI) revenue up 5% to $669.6 million, and CooperSurgical (CSI) revenue up 8% to $332.7 million.GAAP diluted earnings per share (EPS) of $0.44, consistent with last year's second quarter.Non-GAAP diluted EPS of $0.96, up $0.11 or 14% from last year's second quarter. See "Reconciliation of Selected GAAP Results to Non-GAAP Results" below. Commenting on the results, Al White, CooperCompanies' President and CEO said,

    5/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care

    CooperCompanies Announces Release Date for Second Quarter 2025

     SAN RAMON, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading medical device company, announced today it will report second quarter 2025 financial results on Thursday, May 29, 2025, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments. The dial-in number for the call is 800-715-9871 and the conference ID is 1515103. A simultaneous audio webcast and subsequent replay can be accessed at http://investor.coopercos.com. About CooperCompaniesCooperCompanies (NASDAQ:COO) is a leading global medical device company focused on helping people experience life's beautiful

    4/29/25 4:15:00 PM ET
    $COO
    Ophthalmic Goods
    Health Care